Summit X LLC’s GSK GSK Stock Holding History

Summit X LLC’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,022	Closed	-$506K	–	183
2017 Q3	$506K	Sell	10,022 -2,373	-19%	-$120K	0.34%	77
2017 Q2	$665K	Buy	+12,395	New	+$661K	0.47%	59

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Summit X LLC's GSK Position: Q4 2017 in Review

Summit X LLC sold out of GSK (GSK) in Q4 2017, closing a stake of 10,022 shares — an estimated $506K sold.

Summit X LLC first reported a position in GSK in Q2 2017 and held it in 2 quarters. The position peaked at $665K in Q2 2017. 764 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

Summit X LLC reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
Summit X LLC sold 10,022 GSK shares in Q4 2017, an estimated $506K.
Summit X LLC first reported a position in GSK in Q2 2017 and held it in 2 quarters.
Summit X LLC's GSK position peaked at $665K in Q2 2017.
764 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on Summit X LLC's 13F filing for Q4 2017, filed 23 Jan 2018.